Today, Congressman Joe Pitts (R-PA), Chairman of the Energy and Commerce Committee's Health Subcommittee, and Congressman Frank Pallone, Jr. (D-NJ), Ranking Member of the Health Subcommittee, introduced the Improving Regulatory Transparency for New Medical Therapies Act. The bipartisan legislation seeks to improve the transparency and consistency of Drug Enforcement Agency review of pharmaceuticals.
H.R. 4299 improves the DEA scheduling process for new FDA-approved drugs under the Controlled Substances Act and the registration process for the use of controlled substances in clinical trials. This will allow safe and innovative treatments to get to patients in a more timely and predictable manner.
"In recent years, we've successfully worked together across party lines to make the review of critical new medications more efficient, predictable and transparent," said Pitts. "Our new legislation is another cooperative effort to make sure patients get timely access to the latest therapies safely."
"I'm proud to work with Chairman Pitts on this critical initiative that will bring better reliability and transparency to breakthrough therapies, while continuing to ensure that they reach those in need both safely and effectively," said Pallone. "This bill will help further the innovation already occurring throughout the medical community and continues our committee's important bipartisan efforts to improve the drug approval framework."